Step 1 of 2
Explore systemic therapy and CNS management of breast cancer brain metastases beyond HER2-positive disease, including evidence for antibody–drug conjugates (ADCs) in metastatic triple-negative and HR-positive/HER2-negative breast cancer. Review ADC-associated adverse event management, ongoing clinical trials, and the role of brain MRI in evaluating suspected progression and treatment-related changes.